S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Paul Cheng - Analyst Performance

This page shows the methodology used to calculate Scotiabank analyst Paul Cheng's recommendation performance. Listed below are links to the research notes issued, the price targets issued by the analyst, and the stock's actual price 12 months from the date the research note was issued. These rankings are based on research reports from 11/29/2018 and 11/29/2022. Rankings are updated daily.

Average 12-Month ROI of Buy and Strong Buy Recommendations: ???%

MarketBeat Analyst Ranking: starstarxxx
CompanyReport DateReport Date Price12-Month
Price Target
Rating12-Month
Actual Price
12-Month
ROI
Details

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.



How are MarketBeat's Analyst Rankings Calculated? MarketBeat uses the average return on investment of an analyst's "buy" and "strong buy" recommendations over the last five years to determine their star rating. The firms with the best-performing recommendations receive a five-star rating. Analysts that have issued fewer than five tracked research notes in the last five years will not be ranked.

Return to Analyst Rankings

My Account -